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Therapeutic drug monitoring (TDM) of antibiotics is employed
only for aminoglycosides, chloramphenicol and, arguably,
vancomycin.1-4
Aminoglycosides are first-line antibiotics in treating
infections of Gram-negative micro-organisms that are resistant
to less toxic agents.2 They have potent concentration-
dependent bactericidal activity, a post-antibiotic effect (PAE),
relatively predictable pharmacokinetics and act synergistically
with many other antibiotics.  With susceptible organisms,
clinical responses are rapid and understanding their toxicity
profiles has allayed fears relating to adverse effects of these
drugs (principally nephro- and ototoxicity).  
TDM of aminoglycosides is costly and some controversy
exists with regard to its role in patients with adequate renal
function.2,3 The serum levels in such patients must be carefully
interpreted, since pharmacokinetics may be altered by many
factors other than renal function.5,6
Aminoglycosides are administered by traditional or pulse-
dosing regimens, i.e. they may be given in divided doses thrice
daily or as a bolus (total daily dose) 24-hourly.2 With pulse-
dosing, toxicity and costs (logistical and TDM) may decrease
and higher plasma concentrations could improve their PAE.  
Resistance to aminoglycosides may be due to decreased
antibiotic uptake/accumulation and efflux from the organism,
modification of the ribosomal target as well as enzymatic
degradation of the drug.7 Except for amikacin, the latter
mechanism appears to be the primary cause of acquired
resistance to these drugs.  
In view of the above, it was the aim of this study to
investigate the demands for blood level determinations of
amikacin, gentamicin, netilmicin and tobramycin over the past
13 years in the Western Cape, to compare these results with
resistance patterns and to discuss the patterns in terms of
changed dosing regimens, costs and published literature.
Methods and materials
The Pharmacology/Toxicology Laboratory of Stellenbosch
University and Tygerberg Academic Hospital provides a 24-
hour service, primarily to the Tygerberg Academic Hospital,
but also an after-hours service to Groote Schuur, Victoria, Red
Cross, 2 Military and a number of satellite hospitals.  As a
result, this laboratory processes the largest number of
specimens by a single laboratory in the Western Cape. The total
requests received for TDM of aminoglycosides, which in 1991
and 2004 numbered 8 585 and 2 204, respectively, are therefore
probably the best available reflection of the demand for these
analyses, and by extrapolation, the usage of aminoglycosides,
in the Western Cape.
Laboratory records from the Pharmacology/Toxicology
Laboratory of Stellenbosch University and Tygerberg Academic
Hospital were examined, spanning the period 1991 - 2004.  The
number of requests for serum determinations of four
aminoglycosides, i.e. amikacin, gentamicin, netilmicin and
tobramycin, was extracted from these records.  All routine
serum determinations of the aminoglycosides are performed
quantitatively by means of a fluorescence polarisation
immunoassay (FPIA) technique.  The data were transferred to
an Excel spreadsheet (Microsoft Incorporated, Seattle, USA).
Hereafter, the number of requests for determinations
performed (totals per month and totals per year between 1991
and 2003) was plotted for each aminoglycoside using
GraphPad Prism software (GraphPad Software Inc, San Diego,
USA).
Similarly, laboratory records from the Department of Medical
Microbiology of Stellenbosch University and Tygerberg
Academic Hospital were examined, spanning the period
October 2002 - September 2004.  The number of organisms that
were exposed to amikacin, gentamicin and tobramycin,
excluding netilmicin, the latter being primarily used in the
private sector, as well as their susceptibility profiles, was
obtained from these records.  Acinetobacter species was chosen
as an example of a bacterium that demonstrated a relatively
high level of resistance to aminoglycosides in comparison with
other organisms of which fairly large numbers were also tested.
Acinetobacter species, in particular Acinetobacter baumannii, has
been associated with a number of clinically significant
infections in Tygerberg Academic Hospital, Johannesburg
Hospital and other hospitals worldwide.8,9 The data were again
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transferred to an Excel spreadsheet (Microsoft Incorporated,
Seattle, USA).  Hereafter, the percentage of Acinetobacter
species, as well as A. baumannii, that was resistant to amikacin,
gentamicin and tobramycin, was plotted (in 6-monthly
intervals for the period October 2002 - September 2004) using
GraphPad Prism software (GraphPad Software Inc, San Diego,
USA).
Results
The number of analyses for amikacin, gentamicin, netilmicin
and tobramycin for the period 1991 - 2004 (requested per
month and per year) are shown in Figs 1 and 2, respectively.
The percentage of Acinetobacter species and A. baumannii that
were resistant to amikacin, gentamicin and tobramycin for the
period October 2002 - September 2004 (divided into 6-monthly
intervals) are shown in Figs 3 and 4, respectively.
Discussion
Several of the previously mentioned hospitals, other than
Tygerberg Academic Hospital, as well as certain private
pathology laboratories, provide their own daytime analytical
services for serum determination of aminoglycosides.   As a
result of these daytime services, data obtained from the current
study are therefore necessarily somewhat conservative with
regard to the true usage and demand for aminoglycoside TDM
in the Western Cape.
The data on microbial resistance reflect only the patterns at
Tygerberg Academic Hospital, since the Department of Medical
Microbiology of Stellenbosch University and Tygerberg
Academic Hospital performs these determinations only for this
particular institution.
From the number of serum level requests per month (average
approximately 3 000) (Fig. 1) it appears that peaks occurred in
early winter and spring for amikacin TDM, therefore reflecting
a seasonal pattern in the demand for analyses for this
aminoglycoside antibiotic.  A similar pattern was observed for
netilmicin and tobramycin, with monthly totals for these two
agents approximating 16 and 50 analyses, respectively.
However, in contrast, this did not appear to be the case for
gentamicin, for which the monthly demand remained relatively
constant at approximately 2 000.   While no definite
explanation can be given for these observations, one may
speculate that the increased number of seasonally related
requests is associated with a higher incidence of infections
occurring during winter and early spring.
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Fig. 1. Total number of analyses for aminoglycosides requested per
month (1991 - 2004).
Fig. 3. Percentage of Acinetobacter species resistant to amikacin,
gentamicin and tobramycin.
Fig. 2. Total number of analyses for aminoglycosides requested per
year (1999 - 2004).
Fig. 4. Percentage of Acinetobacter baumannii resistant to
amikacin, gentamicin and tobramycin.
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